CorrectSequence Therapeutics Reports Positive 15-Month Follow-Up Data for Sickle Cell Disease Therapy
Rapid Read

CorrectSequence Therapeutics Reports Positive 15-Month Follow-Up Data for Sickle Cell Disease Therapy

What's Happening? CorrectSequence Therapeutics, a biotechnology company, has announced promising results from a clinical trial involving its high-precision base-editing therapy, CS-206, for sickle cell disease (SCD). The therapy has shown efficacy in preventing vaso-occlusive crises (VOCs) and anemi
AI Generated
This may include content generated using AI tools. Glance teams are making active and commercially reasonable efforts to moderate all AI generated content. Glance moderation processes are improving however our processes are carried out on a best-effort basis and may not be exhaustive in nature. Glance encourage our users to consume the content judiciously and rely on their own research for accuracy of facts. Glance maintains that all AI generated content here is for entertainment purposes only.